BGPT: Author Review: Ying Yang

Explore by Goal

Quick Explanation Copied

Ying Yang (as represented by the supplied “Hui Ying Yang” record) appears scientifically strong: the included set spans mechanistic cell biology, functional genomics, cancer biology, antimicrobial virulence, and material science. Across the provided papers, the most rigorous evidence quality is dominated by multi-constraint mechanistic validation (genetic perturbations + molecular readouts + orthogonal assays) and omics resources with public data (e.g., GEO/MassIVE/SRA). Weak spots in the supplied evidence are mostly general translational uncertainty (model-to-human extrapolation), and reproducibility gaps when raw data/code are not openly deposited.

Long Explanation

Author Review: Ying Yang — Evidence Strength Audit

Scope: I only evaluate what’s explicitly present in the provided data dump: a set of paper-level summaries/extracts (with DOIs), plus an OpenAlex-style author record snippet.
Epistemic stance: evidence below is not treated as universally true across all “Ying Yang” individuals with the same name; it’s evaluated only for the specific works and metrics you included.

1) What this author’s supplied work most strongly demonstrates

Mechanistic depth with orthogonal readouts is common in the supplied set. Example: caveolin-mediated “raft-domain gating” of NGF signaling uses genetic perturbations (Cav-1/Cav-2 and Cav-1 S80V), trafficking localization, and downstream phosphorylation/nuclear signaling readouts, supporting an opposing functional model for Cav-1 vs Cav-2 (molecular domain logic rather than single-marker correlation) .
“Causal axis” logic in cancer signaling appears in the TNBC work: multi-level evidence connects BPNT1 expression/prognosis to a mechanistic protein axis (STUB1-mediated LIMA1 destabilization), and then to functional outcomes (EMT, invasion, metastasis) plus drug-response sensitivity .
High-resolution functional genomics resources: eScreen is described as learning CRE function/grammar at single-nucleotide resolution from a large perturbation compendium and validating via CRISPRi and base editing, with raw data deposition and code availability emphasized in the supplied extract .
Cellular fate control via transcriptional circuitry: the NANOG–TBX3–GATA6 switch in primitive endoderm differentiation is supported by CRISPR perturbations, chromatin profiling (RNA-seq/ChIP-seq), reporter assays, and enhancer activation/repression logic in the supplied extract .

2) Visual evidence: where the supplied work gives quantitative outcomes

Below I visualize one quantitatively extracted result-set (the neuromodulation meta-analysis extract). This is the cleanest, directly numeric portion in your provided dataset.

Citation basis: The Hedges g point estimates and confidence intervals are taken from your supplied systematic review/meta-analysis extract (random-effects models with Hedge’s g, heterogeneity reported via I²) .

Critical note (epistemic humility): the visual does not correct for clinical heterogeneity in stimulation parameters or patient selection, and the extract itself flags substantial heterogeneity (high I²) .

3) Rigor & reproducibility: strengths and recurring blind spots in the supplied set

Public deposition where available appears in multiple supplied works, which strengthens reproducibility. Examples include: SenCat (GEO Mass spectrometry and GEO accessions stated) , and eScreen (GSA-Human accession and public code/server links) .
Orthogonal causality tests are often included (genetic perturbation + molecular mechanistic assays + functional phenotypes). Example: kindlin-2–moesin regulation of angiogenesis uses endothelial-specific genetics, membrane tension measurements, VEGFR2 endocytosis assays, and retinal pathologic neovascular models .
However, model-to-human translation remains a systematic blind spot in multiple domains. Example limitations explicitly noted in the supplied extract for the NGF/caveolin work include overexpression/raft extraction artifacts and limited generalization beyond specific neuronal contexts .
Publication bias risk is relevant when outcomes are uniformly positive and when raw negative-result reporting isn’t available. Your MOF theranostic review extract explicitly raises challenges like toxicity/biosafety, long-term fate, and translation gaps—signaling that even when many preclinical reports exist, synthesis needs careful bias control .
Genome editing specificity/toxicity questions are partially addressed in some supplied editor papers, but in vivo long-term safety remains underdetermined in many extracts. Example: Cas12j-8 nuclease work is described as showing high specificity with GUIDE-seq and activity across loci, but the extract also states that in vivo validation and long-term safety/immunogenicity are still needed .

4) Cross-paper scientific “profile” (what seems to be the author’s strong style)

Multi-level evidence stacking: frequently combines cell biology with molecular mechanism and in vivo or system-level validation (e.g., kindlin-2–moesin angiogenesis and caveolin NGF signaling are mechanistically focused with functional outputs) .
Use of datasets/resources and explicit computational workflows appears in functional genomics and multi-omics aging: SenCat emphasizes multi-omic signatures and ML scoring with deposited datasets .
Broad domain coverage (cancer, immunotherapy, microbiology anti-virulence, circadian clock regulation, and materials) could be either a strength (cross-disciplinary transfer) or a risk (outsized confidence without deep domain-local replication). The current provided evidence can’t disambiguate either possibility because it’s not an exhaustive publication record and doesn’t include independent lab replication for each claim.

5) What would most likely disprove or downgrade the author’s claims (in the supplied set)

Generalization failures: many mechanisms are shown in specific model systems (cell lines, mouse strains, particular bacterial isolates). If independent cohorts/strains/cell types don’t reproduce the axis, mechanistic certainty would drop. This caution is explicitly consistent with multiple supplied extracts (e.g., raft gating artifacts and generalization concerns) .
Translational disconnects: immune modulation localization (e.g., magnetically activatable baculoviral vectors) might look impressive in a single tumor model but fail across tumor types or in deeper tissues; long-term systemic safety and editing permanence must be established. The supplied MBV-Pdl1 extract flags limited tumor models and the need for broader validation and long-term safety .
Reproducibility gaps where code/data are not publicly deposited can be used to re-evaluate results. When deposition is stated (e.g., eScreen, SenCat), this risk is reduced .

Bottom-line scientific assessment (from the supplied set only)

Across the supplied evidence, the work displays high mechanistic sophistication and frequent integration of multi-omic or molecularly grounded assays, with several examples of explicit dataset deposition and computational reproducibility support. The main reasons to remain skeptical are translation/generalization uncertainty (models vs humans; isolate-specific microbiology; system-specific mechanistic context) and selective availability of raw data/code in some extracts.

Data integrity warning: “Ying Yang” is ambiguous. Your supplied OpenAlex-style snippet contains multiple “Ying Yang” variants; I therefore evaluate only the specific paper DOIs and extracts you provided.

Feedback:

Updated: March 29, 2026